Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Figure 1Loading Img

Brain-Specific Delivery of Dopamine Mediated by N,N-Dimethyl Amino Group for the Treatment of Parkinson’s Disease

View Author Information
Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, Sichuan University, Sichuan, People’s Republic of China
*Telephone: +86-28-85501566. Fax: +86-28-85501615. E-mail: [email protected]
Cite this: Mol. Pharmaceutics 2014, 11, 9, 3174–3185
Publication Date (Web):July 29, 2014
https://doi.org/10.1021/mp500352p
Copyright © 2014 American Chemical Society

    Article Views

    1250

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options
    Supporting Info (1)»

    Abstract

    Abstract Image

    Parkinson’s disease (PD) has become one of the most deadly diseases due to a lack of effective treatment. Herein, N-3,4-bis(pivaloyloxy)dopamine-3-(dimethylamino)propanamide (PDDP), a brain-specific derivative of dopamine, was designed and synthesized, which consists of a brain targeted ligand, N,N-dimethyl amino group, and two dipivaloyloxy groups for lipophilic modification. PDDP was investigated both in vitro and in vivo by comparing with L-DOPA and another derivative (BPD) without N,N-dimethyl amino group. PDDP showed a more pronounced accumulation in mouse brain microvascular endothelial cells (bEnd.3) than BPD via an active transport process. The increased cellular uptake of PDDP was proven to be mediated by putative pyrilamine cationic transporters. Following intravenous administration, the concentration of PDDP in the brain was 269.28-fold and 6.41-fold higher than that of L-DOPA and BPD at 5 min, respectively. Additionally, PDDP effectively attenuated the striatum lesion caused by 6-hydroxydopamine (6-OHDA) in rats. More importantly, PDDP presented antioxidant and antiapoptotic effects on 6-OHDA-induced toxicity in human neuroblastoma cells (SH-SY5Y). Thus, N,N-dimethyl amino group-based PDDP represents an effective and safe treatment for PD.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    ARTICLE SECTIONS
    Jump To

    Additional experimental details and figures including the synthetic methods and structure confirmation. This material is available free of charge via the Internet at http://pubs.acs.org.

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

    Cited By

    This article is cited by 19 publications.

    1. Pol Arranz-Gibert, Bernat Guixer, Morteza Malakoutikhah, Markus Muttenthaler, Fanny Guzmán, Meritxell Teixidó, and Ernest Giralt . Lipid Bilayer Crossing—The Gate of Symmetry. Water-Soluble Phenylproline-Based Blood-Brain Barrier Shuttles. Journal of the American Chemical Society 2015, 137 (23) , 7357-7364. https://doi.org/10.1021/jacs.5b02050
    2. Xinyi Wang, Jianbo Li, Chaoqun Xu, Yanping Li, Tao Gong, Xun Sun, Yao Fu, Qin He, and Zhirong Zhang . Scopine as a Novel Brain-Targeting Moiety Enhances the Brain Uptake of Chlorambucil. Bioconjugate Chemistry 2014, 25 (11) , 2046-2054. https://doi.org/10.1021/bc5004108
    3. Toshihiko Tashima. Carrier-Mediated Delivery of Low-Molecular-Weight N-Containing Drugs across the Blood–Brain Barrier or the Blood–Retinal Barrier Using the Proton-Coupled Organic Cation Antiporter. Future Pharmacology 2023, 3 (4) , 742-762. https://doi.org/10.3390/futurepharmacol3040046
    4. Qiang Zhang, Yikun Han, Honglin Xiang, Min Li, Lan Yang, Qiang Liu, Yan Zhang, Zhirong Zhang, Qing Lin, Ling Zhang. Biopharmaceutical, preclinical pharmacokinetic and pharmaco-dynamic investigations of an orally administered novel 3-nbutylphthalide prodrug for ischemic stroke treatment. European Journal of Pharmaceutical Sciences 2023, 180 , 106308. https://doi.org/10.1016/j.ejps.2022.106308
    5. Shuo Zhang, Shuai Zhang, Siyuan Luo, Peng Tang, Mingxi Wan, Daocheng Wu, Wei Gao. Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect. Journal of Nanobiotechnology 2022, 20 (1) https://doi.org/10.1186/s12951-022-01464-z
    6. Min-Hui Cao, Bao-He Tang, Yao Ruan, Xiao-Long Liang, Xin-Yi Chu, Zhan-Min Liang, Qing-Ye Zhang, Hong-Yu Zhang. Development of specific and selective bactericide by introducing exogenous metabolite of pathogenic bacteria. European Journal of Medicinal Chemistry 2021, 225 , 113808. https://doi.org/10.1016/j.ejmech.2021.113808
    7. Honglin Xiang, Qiang Zhang, Yikun Han, Lan Yang, Yan Zhang, Qiang Liu, Zhirong Zhang, Ling Zhang. Novel brain-targeting 3-n-butylphthalide prodrugs for ischemic stroke treatment. Journal of Controlled Release 2021, 335 , 498-514. https://doi.org/10.1016/j.jconrel.2021.05.045
    8. Xue Xia, Yang Zhou, Huile Gao. Prodrug strategy for enhanced therapy of central nervous system disease. Chemical Communications 2021, 18 https://doi.org/10.1039/D1CC02940A
    9. Roberta Cassano, Adriana Trapani, Maria Luisa Di Gioia, Delia Mandracchia, Rosalia Pellitteri, Giuseppe Tripodo, Sonia Trombino, Sante Di Gioia, Massimo Conese. Synthesis and characterization of novel chitosan-dopamine or chitosan-tyrosine conjugates for potential nose-to-brain delivery. International Journal of Pharmaceutics 2020, 589 , 119829. https://doi.org/10.1016/j.ijpharm.2020.119829
    10. Govindarajan Karthivashan, Palanivel Ganesan, Shin-Young Park, Ho-Won Lee, Dong-Kug Choi. Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies. Biomaterials 2020, 232 , 119704. https://doi.org/10.1016/j.biomaterials.2019.119704
    11. Fatemeh Moradi, Houman Parsaie, Enam Alhagh Charkhat Gorgich. Targeted Delivery of Therapeutic Agents by Smart Nanocarrier for Treatment of Parkinson’s Disease: A Novel Brain Targeting Approach. Gene, Cell and Tissue 2019, In Press (In Press) https://doi.org/10.5812/gct.91213
    12. Mengke Qu, Qing Lin, Luyi Huang, Yao Fu, Luyao Wang, Shanshan He, Yu Fu, Shengyong Yang, Zhirong Zhang, Ling Zhang, Xun Sun. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson's disease. Journal of Controlled Release 2018, 287 , 156-166. https://doi.org/10.1016/j.jconrel.2018.08.035
    13. Andrea Shergalis, Armand Bankhead, Urarika Luesakul, Nongnuj Muangsin, Nouri Neamati, . Current Challenges and Opportunities in Treating Glioblastoma. Pharmacological Reviews 2018, 70 (3) , 412-445. https://doi.org/10.1124/pr.117.014944
    14. Mengke Qu, Qing Lin, Shanshan He, Luyao Wang, Yao Fu, Zhirong Zhang, Ling Zhang. A brain targeting functionalized liposomes of the dopamine derivative N -3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease. Journal of Controlled Release 2018, 277 , 173-182. https://doi.org/10.1016/j.jconrel.2018.03.019
    15. Xinyi Wang, Bowen Qi, Huifang Su, Jianbo Li, Xun Sun, Qin He, Yao Fu, Zhirong Zhang. Pyrilamine-sensitive proton-coupled organic cation (H+/OC) antiporter for brain-specific drug delivery. Journal of Controlled Release 2017, 254 , 34-43. https://doi.org/10.1016/j.jconrel.2017.03.034
    16. Banu Cahide Tel, Gul Yalçin Çakmakli. Parkinson’s Disease. 2017, 241-269. https://doi.org/10.1016/B978-0-12-803796-6.00013-7
    17. Yanping Li, Yangyang Zhou, Jiayu Jiang, Xinyi Wang, Yao Fu, Tao Gong, Xun Sun, Zhirong Zhang. Mechanism of Brain Targeting by Dexibuprofen Prodrugs Modified with Ethanolamine-Related Structures. Journal of Cerebral Blood Flow & Metabolism 2015, 35 (12) , 1985-1994. https://doi.org/10.1038/jcbfm.2015.160
    18. Toshihiko Tashima. Intriguing possibilities and beneficial aspects of transporter-conscious drug design. Bioorganic & Medicinal Chemistry 2015, 23 (15) , 4119-4131. https://doi.org/10.1016/j.bmc.2015.06.022
    19. Xin Ji, Wentao Wang, Hedi Mattoussi. Effects of separation distance on the charge transfer interactions in quantum dot–dopamine assemblies. Physical Chemistry Chemical Physics 2015, 17 (15) , 10108-10117. https://doi.org/10.1039/C5CP00462D